-
1
-
-
84879556643
-
-
San Diego, CA: Amylin Pharmaceuticals
-
Byetta (exenatide) package insert. San Diego, CA: Amylin Pharmaceuticals; 2011.
-
(2011)
Byetta (Exenatide) Package Insert
-
-
-
2
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132:2131-57.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
5
-
-
0018758893
-
The incretin concept today
-
Creutzfeldt W. The incretin concept today. Diabetologia. 1979; 16:75-85.
-
(1979)
Diabetologia
, vol.16
, pp. 75-85
-
-
Creutzfeldt, W.1
-
6
-
-
0022461548
-
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
-
Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986; 63:492-8.
-
(1986)
J Clin Endocrinol Metab
, vol.63
, pp. 492-498
-
-
Nauck, M.A.1
Homberger, E.2
Siegel, E.G.3
-
7
-
-
0033766716
-
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
-
Deacon CF, Nauck MA, Meier J et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000; 85:3575-81.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 3575-3581
-
-
Deacon, C.F.1
Nauck, M.A.2
Meier, J.3
-
8
-
-
2942670571
-
Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency
-
Meier C, Liu PY, Ly LP et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab. 2004;89:3033-41.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 3033-3041
-
-
Meier, C.1
Liu, P.Y.2
Ly, L.P.3
-
9
-
-
33751506355
-
The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
-
Vilsboll T, Agerso H, Lauritsen T et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept. 2006;137:168-72.
-
(2006)
Regul Pept
, vol.137
, pp. 168-172
-
-
Vilsboll, T.1
Agerso, H.2
Lauritsen, T.3
-
10
-
-
0018193765
-
Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man
-
Buchan AM, Polak JM, Capella C et al. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 1978; 56:37-44.
-
(1978)
Histochemistry
, vol.56
, pp. 37-44
-
-
Buchan, A.M.1
Polak, J.M.2
Capella, C.3
-
12
-
-
0033520869
-
GIP biology and fat metabolism
-
Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000; 66:91-103.
-
(2000)
Life Sci
, vol.66
, pp. 91-103
-
-
Yip, R.G.1
Wolfe, M.M.2
-
13
-
-
0028803336
-
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
-
Deacon CF, Nauck MA, Toft-Nielsen M et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995; 44:1126-31.
-
(1995)
Diabetes
, vol.44
, pp. 1126-1131
-
-
Deacon, C.F.1
Nauck, M.A.2
Toft-Nielsen, M.3
-
14
-
-
0141446228
-
Enhancing incretin action for the treatment of type 2 diabetes
-
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26:2929-40.
-
(2003)
Diabetes Care
, vol.26
, pp. 2929-2940
-
-
Drucker, D.J.1
-
15
-
-
84930476726
-
Anti-inflammatory properties of exenatide in human pancreatic cells
-
Cechin SR, Perez-Alvarez I, Fenjves E et al. Anti-inflammatory properties of exenatide in human pancreatic cells. Cell Transplant. 2012; 21:633-48.
-
(2012)
Cell Transplant
, vol.21
, pp. 633-648
-
-
Cechin, S.R.1
Perez-Alvarez, I.2
Fenjves, E.3
-
16
-
-
74049087761
-
Liraglutide induces cell proliferation and protects from interleukin-1beta induced beta-cell apoptosis in human islets
-
Abstract
-
Prazak R, Rütti S, Ellingsgaard H et al. Liraglutide induces cell proliferation and protects from interleukin-1beta induced beta-cell apoptosis in human islets. Diabetes. 2008; 57(suppl 1):1573-P. Abstract.
-
(2008)
Diabetes
, vol.57
, pp. 1573-P
-
-
Prazak, R.1
Rütti, S.2
Ellingsgaard, H.3
-
17
-
-
39749143348
-
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus
-
Vilsbøll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008; 25:152-6.
-
(2008)
Diabet Med
, vol.25
, pp. 152-156
-
-
Vilsbøll, T.1
Brock, B.2
Perrild, H.3
-
18
-
-
27744541052
-
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
-
Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:5991-7.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 5991-5997
-
-
Fehse, F.1
Trautmann, M.2
Holst, J.J.3
-
19
-
-
85077296846
-
Effects of exenatide on palmitate-induced inflammation and insulin resistance in skeletal muscle
-
Abstract
-
Sinha S, Sathyanarayana P, Jogi M et al. Effects of exenatide on palmitate-induced inflammation and insulin resistance in skeletal muscle. Diabetes. 2008; 57(suppl 1):1266-P. Abstract.
-
(2008)
Diabetes
, vol.57
, pp. 1266-P
-
-
Sinha, S.1
Sathyanarayana, P.2
Jogi, M.3
-
20
-
-
63249084223
-
Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver
-
Zheng D, Ionut V, Mooradian AD et al. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes. 2009; 58:352-9.
-
(2009)
Diabetes
, vol.58
, pp. 352-359
-
-
Zheng, D.1
Ionut, V.2
Mooradian, A.D.3
-
21
-
-
0038497464
-
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
-
Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88:3082-9.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 3082-3089
-
-
Kolterman, O.G.1
Buse, J.B.2
Fineman, M.S.3
-
22
-
-
33644618433
-
The biology of incretin hormones
-
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3:153-65.
-
(2006)
Cell Metab
, vol.3
, pp. 153-165
-
-
Drucker, D.J.1
-
23
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109:962-5.
-
(2004)
Circulation
, vol.109
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
-
24
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
Sokos GG, Nikolaidis LA, Mankad S et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12:694.
-
(2006)
J Card Fail
, vol.12
, pp. 694
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
-
25
-
-
0026795135
-
Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4
-
Raufman JP, Singh G, Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem. 1992; 267:21432-7.
-
(1992)
J Biol Chem
, vol.267
, pp. 21432-21437
-
-
Raufman, J.P.1
Singh, G.2
Eng, J.3
-
26
-
-
0033151448
-
Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro
-
Tracy MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999; 20:1057-62.
-
(1999)
Biomaterials
, vol.20
, pp. 1057-1062
-
-
Tracy, M.A.1
Ward, K.L.2
Firouzabadian, L.3
-
27
-
-
78649911161
-
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing
-
Fineman M, Flanagan S, Taylor K et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011; 50:65-74.
-
(2011)
Clin Pharmacokinet
, vol.50
, pp. 65-74
-
-
Fineman, M.1
Flanagan, S.2
Taylor, K.3
-
28
-
-
34249891874
-
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
-
Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30:1487-93.
-
(2007)
Diabetes Care
, vol.30
, pp. 1487-1493
-
-
Kim, D.1
MacConell, L.2
Zhuang, D.3
-
29
-
-
73549096393
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes
-
Iwamoto K, Nasu R, Yamamura A et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. 2009; 56:951-62.
-
(2009)
Endocr J
, vol.56
, pp. 951-962
-
-
Iwamoto, K.1
Nasu, R.2
Yamamura, A.3
-
30
-
-
77953828230
-
DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
-
Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33:1255-61.
-
(2010)
Diabetes Care
, vol.33
, pp. 1255-1261
-
-
Buse, J.B.1
Drucker, D.J.2
Taylor, K.L.3
-
31
-
-
53249142132
-
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
-
Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372:1240-50.
-
(2008)
Lancet
, vol.372
, pp. 1240-1250
-
-
Drucker, D.J.1
Buse, J.B.2
Taylor, K.3
-
32
-
-
79958268386
-
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
-
Taylor K, Gurney K, Han J et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011; 11:9.
-
(2011)
BMC Endocr Disord
, vol.11
, pp. 9
-
-
Taylor, K.1
Gurney, K.2
Han, J.3
-
33
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376:431-9.
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
-
34
-
-
79955960213
-
DURATION-2: Efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
-
Wysham C, Bergenstal R, Malloy J et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011; 28:705-14.
-
(2011)
Diabet Med
, vol.28
, pp. 705-714
-
-
Wysham, C.1
Bergenstal, R.2
Malloy, J.3
-
35
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
-
Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375:2234-43.
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
Van Gaal, L.2
Stranks, S.3
-
36
-
-
84859013614
-
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study
-
Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012; 35:252-8.
-
(2012)
Diabetes Care
, vol.35
, pp. 252-258
-
-
Russell-Jones, D.1
Cuddihy, R.M.2
Hanefeld, M.3
-
37
-
-
79955661908
-
DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
-
Blevins T, Pullman J, Malloy J et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96:1301-10.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 1301-1310
-
-
Blevins, T.1
Pullman, J.2
Malloy, J.3
-
38
-
-
78649337330
-
Improved diabetes treatment satisfaction and weight-related quality of life with both exenatide once weekly and twice daily
-
Kim T, Boye KS, Wintle M et al. Improved diabetes treatment satisfaction and weight-related quality of life with both exenatide once weekly and twice daily. Diabetes. 2008; 57(suppl 1):494-P.
-
(2008)
Diabetes
, vol.57
, pp. 494-P
-
-
Kim, T.1
Boye, K.S.2
Wintle, M.3
-
39
-
-
77956076972
-
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
-
Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33:1300-3.
-
(2010)
Diabetes Care
, vol.33
, pp. 1300-1303
-
-
Buse, J.B.1
Sesti, G.2
Schmidt, W.E.3
-
41
-
-
79959559653
-
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
-
Elashoff M, Matveyenko AV, Gier B et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150-6.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
-
42
-
-
79951704452
-
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis
-
Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010; 33:2349-54.
-
(2010)
Diabetes Care
, vol.33
, pp. 2349-2354
-
-
Garg, R.1
Chen, W.2
Pendergrass, M.3
-
43
-
-
79954994764
-
A cohort study of acute pancreatitis in relation to exenatide use
-
Dore DD, Bloomgren GL, Wenten M et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011; 13:559-66.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 559-566
-
-
Dore, D.D.1
Bloomgren, G.L.2
Wenten, M.3
-
44
-
-
38549162147
-
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
-
Klonoff DC, Buse JB, Nielsen LL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24:275-86.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 275-286
-
-
Klonoff, D.C.1
Buse, J.B.2
Nielsen, L.L.3
-
45
-
-
78149447857
-
Application of adult-learning principles to patient instructions: A usability study for an exenatide once-weekly injection device
-
Lorenzi G, Schreiner B, Osther J et al. Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device. Clin Diabetes. 2010; 28:157-62.
-
(2010)
Clin Diabetes
, vol.28
, pp. 157-162
-
-
Lorenzi, G.1
Schreiner, B.2
Osther, J.3
-
46
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-79.
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
47
-
-
80054090833
-
Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes
-
Bunck MC, Corner A, Eliasson B et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011; 34:2041-7.
-
(2011)
Diabetes Care
, vol.34
, pp. 2041-2047
-
-
Bunck, M.C.1
Corner, A.2
Eliasson, B.3
-
48
-
-
65949122087
-
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial
-
Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009; 32:762-8.
-
(2009)
Diabetes Care
, vol.32
, pp. 762-768
-
-
Bunck, M.C.1
Diamant, M.2
Corner, A.3
-
49
-
-
69249204299
-
β-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes
-
Bunck MC, Diamant M, Corner A et al. β-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes. Diabetes. 2008; 57(suppl 1):104-OR.
-
(2008)
Diabetes
, vol.57
, pp. 104-OR
-
-
Bunck, M.C.1
Diamant, M.2
Corner, A.3
-
50
-
-
0042166232
-
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c)
-
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26:881-5.
-
(2003)
Diabetes Care
, vol.26
, pp. 881-885
-
-
Monnier, L.1
Lapinski, H.2
Colette, C.3
-
51
-
-
33846706458
-
The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
-
Monnier L, Colette C, Dunseath GJ et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007; 30:263-9.
-
(2007)
Diabetes Care
, vol.30
, pp. 263-269
-
-
Monnier, L.1
Colette, C.2
Dunseath, G.J.3
-
52
-
-
67649774247
-
Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
-
Best JH, Boye KS, Rubin RR et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009; 26:722-8.
-
(2009)
Diabet Med
, vol.26
, pp. 722-728
-
-
Best, J.H.1
Boye, K.S.2
Rubin, R.R.3
-
53
-
-
79951689950
-
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment
-
Best JH, Rubin RR, Peyrot M et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011; 34:314-9.
-
(2011)
Diabetes Care
, vol.34
, pp. 314-319
-
-
Best, J.H.1
Rubin, R.R.2
Peyrot, M.3
-
54
-
-
0017360990
-
The measurement of observer agreement for categorical data
-
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159-74.
-
(1977)
Biometrics
, vol.33
, pp. 159-174
-
-
Landis, J.R.1
Koch, G.G.2
-
55
-
-
84871048865
-
-
Thomson Reuters. Red book online. www.thomsonhc.com (accessed 2013 Apr 30).
-
Red Book Online
-
-
-
56
-
-
79956104536
-
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK
-
Beaudet A, Palmer JL, Timlin L et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011; 14:357-66.
-
(2011)
J Med Econ
, vol.14
, pp. 357-366
-
-
Beaudet, A.1
Palmer, J.L.2
Timlin, L.3
-
57
-
-
84864705670
-
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: A simulation analysis
-
Gaebler JA, Soto-Campos G, Alperin P et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012; 8:255-64.
-
(2012)
Vasc Health Risk Manag
, vol.8
, pp. 255-264
-
-
Gaebler, J.A.1
Soto-Campos, G.2
Alperin, P.3
-
58
-
-
84864661021
-
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US
-
Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J MedEcon. 2012; 15(suppl 2):6-13.
-
(2012)
J MedEcon
, vol.15
, pp. 6-13
-
-
Samyshkin, Y.1
Guillermin, A.L.2
Best, J.H.3
-
59
-
-
84866144740
-
Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): Results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study
-
Inagaki N, Atsumi Y, Oura T, et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012; 34:1892-908.
-
(2012)
Clin Ther
, vol.34
, pp. 1892-1908
-
-
Inagaki, N.1
Atsumi, Y.2
Oura, T.3
-
60
-
-
84872084453
-
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study
-
Buse JB, Nauck M, Forst T et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013; 381:117-24.
-
(2013)
Lancet
, vol.381
, pp. 117-124
-
-
Buse, J.B.1
Nauck, M.2
Forst, T.3
-
61
-
-
84867344249
-
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years
-
Norwood P, Liutkus JF, Haber H et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012; 34:2082-90.
-
(2012)
Clin Ther
, vol.34
, pp. 2082-2090
-
-
Norwood, P.1
Liutkus, J.F.2
Haber, H.3
-
62
-
-
84877020930
-
Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (2)
-
Cui YM, Guo XH, Zhang DM et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (2). J Diabetes. 2013; 5:127-35.
-
(2013)
J Diabetes
, vol.5
, pp. 127-135
-
-
Cui, Y.M.1
Guo, X.H.2
Zhang, D.M.3
|